UNSPSC 51372805: Eptazocine hydrobromide

This classification denotes an analgesic agent with the molecular structure C15H21NO.BRH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 865626Y4ON chemically known as 1,6-methano-1h-4-benzazonin-10-ol, 2,3,4,5,6,7-hexahydro-1,4-dimethyl-, hbr (1:1), (1s,6s)-, but more commonly known as eptazocine hydrobromide, which bears US NIH Compound Identifier 155705. European Medicines Agency schedules Eptazocine hydrobromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01924MIG.

UNSPSC 51372805 Eptazocine hydrobromide, a Commodity code, shows minimal recent activity directly aligned with its scope; the recent state and local opportunities posted under this code involve naloxone, prescription fulfillment programs, and generic multi-source pharmaceuticals—categories distinct from eptazocine itself. State and local agencies soliciting pharmaceutical products use this taxonomy inconsistently, and eptazocine procurement does not appear to be a current driver of state and local contract activity. The three opportunities posted since January 2026 reflect broader pharmaceutical procurement across health departments, state HHS commissions, and cooperative purchasing alliances, but none target eptazocine as a named product line.

Recent pharmaceutical solicitations span Florida (Seminole County Community Health for naloxone and drug deactivation systems), Texas (Texas Health and Human Services Commission for direct-to-manufacturer prescription programs), and Minnesota (MMCAP for generic multi-source pharmaceuticals and OTC products across multiple states including Oregon). Seminole County issued IFB 60459723LAS on June 30, 2026, due July 26, 2023, for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries. Texas HHS issued RFI HHS0017013 on April 3, 2026, to explore vendor capacity for direct-to-manufacturer prescription contracting outside traditional pharmacy benefit manager arrangements. Minnesota MMCAP issued an RFP (S1070000015802) on January 20, 2026, due March 26, 2026, for generic pharmaceuticals and OTC products through authorized wholesalers with awards effective July 1, 2026. Given the mismatch between the code's nominal scope and actual recent procurement, eptazocine does not represent an active state and local procurement vector at present.